All Outputs (73)

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. (2019)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Burden, A., Rutter, M., …Study Group, B. (2019). Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 34(4), 769 - 778. https://doi.org/10.1111/jdv.16018

BACKGROUND: The cardiovascular safety profile of biologic therapies used for psoriasis is unclear. OBJECTIVES: To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in pa... Read More about Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study..

Real-world effectiveness of methotrexate, ciclosporin, acitretin and fumaric acid esters for psoriasis: Does treatment history matter? (2019)
Presentation / Conference
Mason, K. J. (2019, August). Real-world effectiveness of methotrexate, ciclosporin, acitretin and fumaric acid esters for psoriasis: Does treatment history matter?. Poster presented at 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA

Background: Real-world effectiveness of the systemic therapies methotrexate (MTX), ciclosporin (CsA), acitretin (ACI) and fumaric acid esters (FAE) prescribed to patients with moderate–severe psoriasis is poorly characterized. Objectives: To deter... Read More about Real-world effectiveness of methotrexate, ciclosporin, acitretin and fumaric acid esters for psoriasis: Does treatment history matter?.

Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. (2019)
Journal Article
Mason, K., Williams, S., Yiu, Z., McElhone, K., Ashcroft, D., Kleyn, C., …Griffiths, C. (2019). Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. British Journal of Dermatology, 181(2), 256 - 264. https://doi.org/10.1111/bjd.17625

BACKGROUND: The persistence and effectiveness of systemic therapies for moderate-to-severe psoriasis in current clinical practice are poorly characterized. OBJECTIVES: To systematically review observational studies investigating the persistence and e... Read More about Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review..

Baseline characteristics of patients registering to the British Association of Dermatologists Biologics and Immunomodulators Register stratified by duration of psoriasis at the time of registration (2019)
Journal Article
Reid, C., Mason, K. J., Esse, S., McElhone, K., Lunt, M., Cordingley, L., …Warren, R. B. (2019). Baseline characteristics of patients registering to the British Association of Dermatologists Biologics and Immunomodulators Register stratified by duration of psoriasis at the time of registration. British Journal of Dermatology, 181, 47

The risk of melanoma in patients with immune-mediated inflammatory diseases exposed to biological therapies: systematic review and meta-analysis (2019)
Presentation / Conference
Esse, S., Mason, K. J., Green, A. C., & Warren, R. B. (2019, July). The risk of melanoma in patients with immune-mediated inflammatory diseases exposed to biological therapies: systematic review and meta-analysis. Poster presented at BRITISH ASSOCIATION OF DERMATOLOGISTS 99TH ANNUAL MEETING, LIVERPOOL, U.K

Biological therapies are used in the treatment of immunemediated inflammatory diseases (IMIDs), including moderateto-severe psoriasis, rheumatoid arthritis (RA), psoriatic arthritis (PsA) and inflammatory bowel disease (IBD). Melanoma is a highly i... Read More about The risk of melanoma in patients with immune-mediated inflammatory diseases exposed to biological therapies: systematic review and meta-analysis.

227 Real-world drug discontinuation of acitretin (ACI), ciclosporin (CsA), fumaric acid esters (FAE) and methotrexate (MTX) in patients with moderate-severe psoriasis (2019)
Journal Article
Mason, K. (2019). 227 Real-world drug discontinuation of acitretin (ACI), ciclosporin (CsA), fumaric acid esters (FAE) and methotrexate (MTX) in patients with moderate-severe psoriasis. Journal of Investigative Dermatology, 139(5), S39. https://doi.org/10.1016/j.jid.2019.03.303

Real-world discontinuation of ACI, CsA, FAE and MTX in patients with moderate-severe psoriasis is poorly characterised. The aim of this study was to determine whether treatment history affects the discontinuation rates of these therapies. The British... Read More about 227 Real-world drug discontinuation of acitretin (ACI), ciclosporin (CsA), fumaric acid esters (FAE) and methotrexate (MTX) in patients with moderate-severe psoriasis.

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. (2019)
Journal Article
Warren, R., Marsden, A., Tomenson, B., Mason, K., Soliman, M., Burden, A., …Smith, C. (in press). Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 180(5), 1069 - 1076. https://doi.org/10.1111/bjd.16776

BACKGROUND: Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. OBJECTIVES: To evaluate demographic, social and clin... Read More about Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study..

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy (2019)
Journal Article
Yiu, Z., Sorbe, C., Lunt, M., Rustenbach, S., Kühl, L., Augustin, M., …Owen, C. M. (2019). Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. British Journal of Dermatology, 180(4), 894 -901. https://doi.org/10.1111/bjd.17421

BACKGROUND: Patients with psoriasis are often concerned about the risk of serious infection associated with systemic psoriasis treatments. OBJECTIVES: To develop and externally validate a prediction model for serious infection in patients with psoria... Read More about Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy.

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (2019)
Journal Article
Yiu, Z., Ashcroft, D., Evans, I., McElhone, K., Lunt, M., Smith, C., …Mason, K. (2019). Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 180(2), 329 - 337. https://doi.org/10.1111/bjd.17036

BACKGROUND: Patients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections. OBJECTIVES: To compare the risk of serious infections associated with infliximab in patients with chronic plaque pso... Read More about Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)..

HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis (2018)
Journal Article
Dand, N., Duckworth, M., Baudry, D., Russell, A., Curtis, C. J., Hyuck Lee, S., …Study Group, B. (2019). HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 143(6), 2120-2130. https://doi.org/10.1016/j.jaci.2018.11.038

BACKGROUND: Biologic therapies can be highly effective for the treatment of severe psoriasis, but response for individual patients can vary according to drug. Predictive biomarkers to guide treatment selection could improve patient outcomes and treat... Read More about HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.

A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies (2018)
Presentation / Conference
Yiu, Z., Mason, K., Barker, J., Hampton, P., McElhone, K., Smith, C., …Burden, D. (2018, August). A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies. Presented at 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic

Background: Previous studies using incomplete trial inclusion and exclusion criteria suggest a difference between the reported effectiveness and safety of biologic therapies between randomised clinical trials (RCT) and real-world populations of patie... Read More about A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies.

The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2018)
Presentation / Conference
Mason, K. J. (2018, August). The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Poster presented at 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic

Background: Whether psoriasis patients exposed to biologic therapies have an elevated risk of KC (basal cell carcinoma [BCC] or cutaneous squamous cell carcinoma [cSCC]) remains uncertain. Objectives: To determine whether such patients were at hig... Read More about The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review (2018)
Presentation / Conference
Williams, S., Mason, K. J., Yiu, Z., McElhone, K., Warren, R. B., & Griffiths, C. E. (2018, August). Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review. Paper presented at 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic

Background: The effectiveness and persistence of biologic therapies is better understood than more commonly prescribed conventional systemic therapies in clinical practice. Objectives: To evaluate large-scale observational studies investigating th... Read More about Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review.

A real-world comparison of effectiveness and safety outcomes between clinical trial eligible and ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2018)
Conference Proceeding
Mason, K. J. (2018). A real-world comparison of effectiveness and safety outcomes between clinical trial eligible and ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Background: There is preliminary evidence that psoriasis patients eligible for clinical trials of biologics are not representative of real-world patients. Objectives: To determine whether patients enrolled in BADBIR identified as eligible or ineli... Read More about A real-world comparison of effectiveness and safety outcomes between clinical trial eligible and ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland (2018)
Journal Article
Garcia-Doval, I., Descalzo, M., Mason, K., Cohen, A., Ormerod, A., Gómez-García, F., …Network, T. P. (2018). Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. British Journal of Dermatology, 179(4), 863-871. https://doi.org/10.1111/bjd.16715

Background Cancer risk following long‐term exposure to systemic immunomodulatory therapies in patients with psoriasis is possible. Objectives To assess a dose–response relationship between cumulative length of exposure to biological therapy and... Read More about Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland.

Missing Information About Study Funding (2018)
Journal Article
Mason, K. J., Barker, J. N., Smith, C. H., Hampton, P. J., Lunt, M., McElhone, K., …Study Group, T. B. (2018). Missing Information About Study Funding. JAMA Dermatology, 154(7), 852. https://doi.org/10.1001/jamadermatol.2018.2319

In the Original Investigation titled “Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible And Ineligible Patients in BADBIR,”1 published online March 28, 2018, there was information omitted regarding study fu... Read More about Missing Information About Study Funding.

THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES (2018)
Presentation / Conference
Mason, K. (2018, June). THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES. Poster presented at 5th World Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden

Introduction: Whether psoriasis patients exposed to biologic therapies have an elevated risk of keratinocyte carcinoma (KC), including basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) remains uncertain. Objective:The aim of t... Read More about THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES.

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. (2018)
Journal Article
Mason. (2018). Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 154(5), 581 - 588. https://doi.org/10.1001/jamadermatol.2018.0183

Importance: Patients with psoriasis enrolled in clinical trials of biologics may not be representative of the real-world population. There is evidence that patients ineligible for such trials have a greater risk of serious adverse events (SAEs), but... Read More about Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR..

509 Association between biologics and major cardiovascular events in adult patients with plaque psoriasis: A cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2018)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Rutter, M., Warren, R., …Ashcroft, D. (2018). 509 Association between biologics and major cardiovascular events in adult patients with plaque psoriasis: A cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138(5), S87. https://doi.org/10.1016/j.jid.2018.03.517

The association between biologics and major cardiovascular events (CVEs) in adult patients with plaque psoriasis is unclear. We used prospective cohort data from BADBIR to compared CVE risk associated with different therapies in participants recruite... Read More about 509 Association between biologics and major cardiovascular events in adult patients with plaque psoriasis: A cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Psychosocial factors partially mediate the relationship between mechanical hyperalgesia and self-reported pain (2018)
Journal Article
Mason, K. J., O'Neill, T. W., Lunt, M., Jones, A. K. P., & McBeth, J. (2018). Psychosocial factors partially mediate the relationship between mechanical hyperalgesia and self-reported pain. Scandinavian Journal of Pain, 18(1), 59-69. https://doi.org/10.1515/sjpain-2017-0109

Background and aims: Amplification of sensory signalling within the nervous system along with psychosocial factors contributes to the variation and severity of knee pain. Quantitative sensory testing (QST) is a non-invasive test battery that assesse... Read More about Psychosocial factors partially mediate the relationship between mechanical hyperalgesia and self-reported pain.